Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Back to 2010: England's New CDF To Go Ahead

This article was originally published in Scrip

Executive Summary

England's new Cancer Drugs Fund is to go ahead with little change to proposals that have proved unpopular with companies. The Association of the British Pharmaceutical Industry says the new system will take patients and companies back to the situation in 2010 before the CDF was set up and that two thirds of CDF-financed drugs will be unavailable by the end of the year. Eisai has slammed the new fund, warning that drugs approved after the CDF closed its doors to funding new products will float in limbo with no clear means of getting to patients.

You may also be interested in...

Eisai Says Lenvatinib Lost in UK Market Access Maze Due To NICE Inaction

Japan's Eisai is considering all options including legal action and reducing its investment in the UK to force NICE to make its potential blockbuster TKI cancer drug lenvatinib available sooner to patients with advanced thyroid cancer via the publicly-funded National Health Service.

NICE In CDF Rethink Says OK To Bosulif For General NHS Use In CML

Pfizer Inc.'s Bosulif (bosutinib) will now become generally available on the UK's publicly-funded NHS for use in certain types of chronic myeloid leukemia after NICE reassessed the tyrosine kinase inhibitor in light of new data and a bigger pro-offered price discount from its manufacturer. The drug was previously only available through the country's controversial Cancer Drugs Fund (CDF).

NICE Rejects BMS' Opdivo As Adult Kidney Cancer Treatment

The UK HTA NICE in draft guidance has rejected Bristol-Myers Squibb Co.'s Opdivo (nivolumab) as a therapy for previously treated advanced renal cell carcinoma in adults, saying the PD-1 inhibitor doesn't offer value for money. It added that it should also not be made available to such patients through the government-funded Cancer Drugs Fund, for the same reasons.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts